July 9th 2025
Delayed cerebral ischemia is a leading complication in the severe form of stroke known as subarachnoid hemorrhage and can result in long-term neurological damage, disability, or death.
Regulatory Authorities have Published a Report on COVID Vaccine Development
July 16th 2020Global regulatory authorities have published a report describing the aligned positions on COVID-19 vaccine development, which were agreed upon by meeting participants of the second workshop on COVID-19 vaccine development.
Roche, Blueprint Medicines Enter $1.7-Billion Deal for Anti-Cancer Drug
July 15th 2020Through the deal, Roche will gain co-commercialization rights to pralsetinib, Blueprint Medicine’s investigational, once-daily oral precision therapy for the treatment of RET-altered non-small cell lung cancer, medullary thyroid cancer, and other types of thyroid cancer
SGS Initiates Clinical Trial of Biophytis’ Treatment for COVID-19 Related Respiratory Failure
July 8th 2020SGS has announced the receipt of approval from Belgium’s Federal Agency for Medicines and Health Products (FAMHP) to begin a new clinical trial of a potential treatment for patients with COVID-19 related respiratory failure.
CHMP Recommends Marketing Authorization for Triple Combination Therapy for Cystic Fibrosis
July 1st 2020EMA’s Committee for Human Medicinal Products (CHMP) has recommended that Kaftrio, a triple combination therapy for the treatment of cystic fibrosis, be authorized for marketing in the European Union.
Genomics England Launches Next-Generation Genomics Research Platform
July 1st 2020Genomics England (GEL) has announced the launch of a next-generation genomics research platform, supported by Lifebit-a deep tech company-and Amazon Web Services (AWS), which will be primarily dedicated for COVID-19 research.
EMA Recommends a Conditional Marketing Authorization for Kidney Transplant Medicine
July 1st 2020The European Medicines Agency (EMA) has recommended a conditional marketing authorization be granted for Idefirix (imlinfidase) for the treatment of highly sensitized adult patients waiting for a kidney transplant.
Phase III Trial Results Demonstrate Benefit of AstraZeneca’s Breztri Aerosphere
June 25th 2020Full results from the Phase III ETHOS trial have demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations in patients with moderate to very severe COPD after treatment with triple-combination therapy Breztri Aerosphere.
ILC Therapeutics Enters Research Agreement with University of St Andrews
June 25th 2020Biotechnology company, ILC Therapeutics, has revealed that it has entered into a research partnership with the University of St Andrews aimed at progressing a therapeutic drug that can treat COVID-19 to clinical trials.
Atriva Therapeutics Announces Clinical Strategy to Treat COVID-19 Patients
May 28th 2020Biopharmaceutical company, Atriva Therapeutics, has announced, in a May 28, 2020 press release, that it will develop ATR-002, an oral small molecule, for treatment of patients with moderate-to-severe COVID-19 that require hospitalization in a Phase II study.